Insight Into Novel Anti-tuberculosis Vaccines by Using Immunoinformatics Approaches
Khan Z. Ualiyeva D. Amissah O.B. Sapkota S. Hameed H.M.A. Zhang T.
2 June 2022Frontiers Media S.A.
Frontiers in Microbiology
2022#13
Tuberculosis (TB), an infectious disease, has been a leading cause of morbidity and mortality for decades. The causative agent of TB is the Mycobacterium tuberculosis (Mtb) which can infects various parts of the body, mainly the lungs in pulmonary TB cases. Mycobacterium bovis Bacillus Calmette–Guerin (BCG) is the only approved vaccine for TB, but its efficiency to combat pulmonary TB is limited. Multidrug-resistant (MDR) TB and extensive drug-resistant (XDR) TB requires the evolution of more potent vaccines. Therefore, this research aims to generate a universal TB subunit vaccine using advanced immunoinformatics techniques. In generating a novel multiepitope subunit vaccine, we selected the conserved and experimentally confirmed antigens Rv0058, Rv0101, and Rv3343. After a rigorous evaluation, the top candidates from predicted Helper T-lymphocytes (HTL), Cytotoxic T-lymphocytes (CTL), and B-cell epitopes were considered potential vaccine candidates. Immunogenicity was enhanced by the addition of an adjuvant to the ultimate construct of the vaccine. B-cell epitopes predictions guaranteed the eventual induction of a humoral response. Thereafter, dynamics simulations and molecular docking validated the vaccine-receptor complex’s stability and high affinity for the immune receptor TLR-3. Also, immune simulations revealed the significantly elevated levels of immunoglobulins such as IgM, cytokines such as interleukin-2, helper T (Th) cells, and cytotoxic T-cell populations. These results agreed with the actual inflammatory response and showed rapid antigen clearance after manifold exposure. Finally, the E. coli K12 strain was confirmed via in-silico cloning for quality expression. Nevertheless, in vivo experiments should be performed to validate the safety of the proposed vaccine and its inherent ability to prevent TB infection. Copyright
drug resistance , immunoinformatics , Mycobacterium tuberculosis , therapeutic vaccine , tuberculosis
Text of the article Перейти на текст статьи
State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China
University of Chinese Academy of Sciences, Beijing, China
Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Diseases, Guangzhou, China
China-New Zealand Joint Laboratory on Biomedicine and Health, Guangzhou, China
Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu, China
Faculty of Biology and Biotechnology, Al-Farabi Kazakh National University, Almaty, Kazakhstan
State Key Laboratory of Respiratory Disease
University of Chinese Academy of Sciences
Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Diseases
China-New Zealand Joint Laboratory on Biomedicine and Health
Chengdu Institute of Biology
Faculty of Biology and Biotechnology
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026